Skip to main content

Table 3 Molecular and clinical characteristics of the analyzed sample cohort

From: DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response

Clinicopathological factors

Number of samples

Median age at diagnosis

65 (range 32-85)

Histological grade

 

Grade 1

18 (24%)

Grade 2

38 (50.7%)

Grade 3

19 (25.3%)

Response

 

Progressive Disease

7 (9.5%)

PR, MC or SD

67 (90.5%)

Tumor size

 

T2

3 (4%)

T3

47 (62.7%)

T4

25 (33.3%)

Lymph node metastasis

 

N0

25 (33.3%)

N1

29 (38.7%)

N2

21 (28%)

Distant metastasis

 

M0

66 (88.0%)

M1

9 (12%)

Stage

 

Stage 2

18 (24%)

Stage 3

46 (61%)

Stage 4

11 (15%)

TP53 mutations

 

Wild type

55 (73.3%)

Mutant

20 (26.7%)

Estrogen receptor status

 

Positive

65 (86.7%)

Negative

10 (13.3%)

Progesteron receptor status

 

Positive

58 (77.3%)

Negative

17 (22.7%)

ErbB2 receptor status

 

Positive

11 (25%)

Negative

33 (75%)

Survival

 

> 5 years

20 (26.7%)

< 5 years

55 (73.3%)

  1. PR: partial response; MC: minimal change; SD: stable disease. Lymph node status was assessed clinically prior to neoadjuvant therapy and does not necessarily correspond to pathological lymph node status. In this context N0 means that no enlarged nodes were felt prior to therapy. N1 corresponds to the presence of palpable and movable ipsilateral axillary lymph nodes suspicious of the presence of metastases while N2 corresponds to fixed ipsilateral axillary lymph nodes and thus very likely to the presence of tumours.